JW74|cas:863405-60-1|西域试剂

JW74,98.32%

产品编号：Bellancom-19739| CAS NO：863405-60-1| 分子式：C₂₄H₂₀N₆O₂S| 分子量：456.52

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-19739	￥800.00	杭州北京（现货）
Bellancom-19739	￥1200.00	杭州北京（现货）
Bellancom-19739	￥2400.00	杭州北京（现货）
Bellancom-19739	￥4000.00	杭州北京（现货）
Bellancom-19739	￥7000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

JW74

产品介绍

JW74 拮抗 LiCl 诱导的经典 Wnt 信号传导的激活，IC₅₀ 为 420 nM。

生物活性

JW74 antagonizes LiCl-induced activation of the canonical Wnt signaling with an IC₅₀ of 420 nM.

体外研究

JW74 shows a reduction of canonical Wnt signaling in the ST-Luc assay with an IC₅₀ of 790 nM. The effect of tankyrase inhibition on cellular viability is tested by performing an MTS assay. The cellular viability of U2OS cells treated for 72 h treatment with 10 μM JW74 is reduced to 80%, relative to DMSO-treated cells. Flow cytometry is also performed to determine the expression marker Ki-67 in U2OS following 48 h treatment with DMSO or 10 uM JW74. Ki-67 expression is reduced from 97.5% in DMSO-treated cells to 86.7% in JW74-treated cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

The in vivo efficacy of JW74 is tested using SW480 cell xenografts. A relatively high dose of JW74 (150 or 300 mg/kg) is used because of a rapid compound degradation in the organism as indicated in the human liver microsome analysis (t_1/2=2.5 minutes) and in pharmacokinetic analyses (after per oral injections: t_1/2=30 minutes and intravenous injections: t_1/2=15 minutes). The presence of JW74 in tumors and plasma is identified by mass spectrometry. JW74 concentration in tumors is in the range 4.2 to 72.1 μmol/kg for JW74 150 mg/kg, 1.9 to 11.1 μmol/kg for JW74 300 mg/kg, and 2.8 μM in plasma for both doses.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 50 mg/mL (109.52 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1905 mL	10.9524 mL	21.9048 mL
5 mM	0.4381 mL	2.1905 mL	4.3810 mL
10 mM	0.2190 mL	1.0952 mL	2.1905 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.75 mg/mL (6.02 mM); Clear solution

此方案可获得 ≥ 2.75 mg/mL (6.02 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.75 mg/mL (6.02 mM); Clear solution

此方案可获得 ≥ 2.75 mg/mL (6.02 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。